Lara Brambilla

Lara Brambilla

Auto-generated profile, based on publicly available information

Lara Brambilla

Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
DGDavide Genini
Davide Genini
LBLara Brambilla
Lara Brambilla
ELErik Laurini
Erik Laurini
JMJessica Merulla
Jessica Merulla
GCGianluca Civenni
Gianluca Civenni
CCCarlo Catapano
Carlo Catapano
Significance: The transcription factor STAT3 is involved in multiple oncogenic signaling pathways and is an attractive therapeutic target. This study shows that a potent inhibitor of STAT3 interferes with mitochondrial activity and protein homeostasis, leading to a synthetic lethality effect in glucose-depleted cancer cells. These findings provide a rationale for novel strategies based on the use of STAT3 inhibitors for cancer treatment.

5 March 2015 in Molecular Oncology
Verified
Journal Article
Open access
LBLara Brambilla
Lara Brambilla
DGDavide Genini
Davide Genini
ELErik Laurini
Erik Laurini
JMJessica Merulla
Jessica Merulla
LPLaurent Perez
Laurent Perez
CCCarlo Catapano
Carlo Catapano
STAT3 is a key element in many oncogenic pathways and, like other transcription factors, is an attractive target for development of novel anticancer drugs. However, interfering with STAT3 functions has been a difficult task and very few small molecule inhibitors have made their way to the clinic. OPB‐31121, an anticancer compound currently in clinical trials, has been reported to affect STAT3 signaling, although its mechanism of action has not been unequivocally demonstrated. In this study, we used a combined computational and experimental approach to investigate the molecular target and the mode of interaction of OPB‐31121 with STAT3. In parallel, similar studies were performed with known STAT3 inhibitors (STAT3i) to validate our approach. Computational docking and molecular dynamics simulation (MDS) showed that OPB‐31121 interacted with high affinity with the SH2 domain of STAT3. Interestingly, there was no overlap of the OPB‐31121 binding site with those of the other STAT3i. Computational predictions were confirmed by in vitro binding assays and competition experiments along with site‐directed mutagenesis of critical residues in the STAT3 SH2 domain. Isothermal titration calorimetry experiments demonstrated the remarkably high affinity of OPB‐31121 for STAT3 with Kd (10 nM) 2–3 orders lower than other STAT3i. Notably, a similar ranking of the potency of the compounds was observed in terms of inhibition of STAT3 phosphorylation, cancer cell proliferation and clonogenicity. These results suggest that the high affinity and efficacy of OPB‐31121 might be related to the unique features and mode of interaction of OPB‐31121 with STAT3. These unique characteristics make OPB‐31121 a promising candidate for further development and an interesting lead for designing new, more effective STAT3i.

19 April 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Anastasia MalekAnastasia Malek
Anastasia Malek
LNLuz-Elena Núñez
Luz-Elena Núñez
MMMarco Magistri
Marco Magistri
LBLara Brambilla
Lara Brambilla
SJSandra Jovic
Sandra Jovic
CCCarlo V. Catapano
Carlo V. Catapano
Deregulated activity of transcription factors (TFs) of the Sp/KLF family, like Sp1, Sp3 and Sp4, and consequent over-expression of Sp-regulated genes occur frequently in human cancers. This provides the rationale for development of inhibitors of Sp TFs as cancer therapeutics. Mithramycin A (MTM-A) is a natural polyketide that binds GC-rich DNA sequences, inhibits activity of Sp TFs and exhibits potent antitumor activity in experimental systems. However, clinical use of MTM-A is limited by the severe toxicity of the compound. Here, we studied two MTM-A analogues, which had been generated by genetically engineering of the MTM-A biosynthetic pathway, and evaluated their activity in human prostate cancer in cell cultures and mouse models. The compounds, named MTM-SDK and MTM-SK, were highly effective in vitro inhibiting proliferation of prostate cancer cells and transcription of Sp-regulated genes by blocking binding of Sp proteins to the gene promoters When administered to mice, both compounds were well tolerated with maximum tolerated doses of MTM-SDK and MTM-SK, respectively, 4- and 32- fold higher than MTM-A. After systemic administration, both compounds were cleared rapidly from the bloodstream but maintained plasma levels well above the active concentrations required in vitro for inhibition of Sp TF activity and cell proliferation. Consistently, MTM-SDK and MTM-SK inhibited transcription of Sp-regulated genes in prostate tumor xenografts and exhibited potent antitumor activity in subcutaneous and metastatic tumor xenograft models with no or minimal toxicity. Taken together, these data indicate that MTM-SDK and MTM-SK possess significantly improved pharmacological and toxicological properties compared to MTM-A and represent promising drugs for treatment of advanced prostate cancer.

18 June 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
MKMadhuri Kalathur
Madhuri Kalathur
ATAlberto Toso
Alberto Toso
JCJingjing Chen
Jingjing Chen
ARAjinkya Revandkar
Ajinkya Revandkar
CDClaudia Danzer-Baltzer
Claudia Danzer-Baltzer
AAAndrea Alimonti
Andrea Alimonti
Enhancement of cellular senescence in tumours triggers a stable cell growth arrest and activation of an antitumour immune response that can be exploited for cancer therapy. Currently, there are only a limited number of targeted therapies that act by increasing senescence in cancers, but the majority of them are not selective and also target healthy cells. Here we developed a chemogenomic screening to identify compounds that enhance senescence in PTEN-deficient cells without affecting normal cells. By using this approach, we identified casein kinase 2 (CK2) as a pro-senescent target. Mechanistically, we show that Pten loss increases CK2 levels by activating STAT3. CK2 upregulation in Pten null tumours affects the stability of Pml, an essential regulator of senescence. However, CK2 inhibition stabilizes Pml levels enhancing senescence in Pten null tumours. Taken together, our screening strategy has identified a novel STAT3–CK2–PML network that can be targeted for pro-senescence therapy for cancer.